FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022101675> ?p ?o ?g. }

• W2022101675 endingPage "391" @default.
• W2022101675 startingPage "391" @default.
• W2022101675 abstract "Letters6 September 2005Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis BMartijn J. ter Borg, MD and Harry L.A. Janssen, MD, PhDMartijn J. ter Borg, MDFrom Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.Search for more papers by this author and Harry L.A. Janssen, MD, PhDFrom Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-5-200509060-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In Chan and colleagues' study of pegylated interferon in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (1), the sustained virologic response (HBeAg seroconversion and hepatitis B virus DNA level less than 500 000 copies/mL) was 36% after 32 weeks of therapy with pegylated interferon-α2b plus 52 weeks of lamivudine. This percentage is comparable with the HBeAg seroconversion rates in 2 global studies investigating combination therapy with pegylated interferon and lamivudine for 1 year (2, 3). In one of these studies, coordinated by our group (2), patients were treated for 52 weeks with pegylated interferon-α2b and ...References1. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005;142:240-50. [PMID: 15710957] LinkGoogle Scholar2. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-9. [PMID: 15639293] CrossrefMedlineGoogle Scholar3. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-95. [PMID: 15987917] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Martijn J. ter Borg, MD; Harry L.A. Janssen, MD, PhDAffiliations: From Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone Henry Lik-Yuen Chan , Nancy Wai-Yee Leung , Alex Yui Hui , Vincent Wai-Sun Wong , Choong-Tsek Liew , Angel Mei-Ling Chim , Francis Ka-Leung Chan , Lawrence Cheung-Tsui Hung , Yuk-Tong Lee , John Siu-Lun Tam , Christopher Wai-Kei Lam , and Joseph Jao-Yiu Sung Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B Henry L.Y. Chan and Joseph J.Y. Sung Metrics Cited byDiagnostik und Therapie der Hepatitis 6 September 2005Volume 143, Issue 5Page: 391KeywordsAntigensChronic hepatitis BConflicts of interestDNAHepatitis BHepatitis B virusInterferonsPatients ePublished: 6 September 2005 Issue Published: 6 September 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ..." @default.
• W2022101675 created "2016-06-24" @default.
• W2022101675 creator A5024994766 @default.
• W2022101675 creator A5043626370 @default.
• W2022101675 date "2005-09-06" @default.
• W2022101675 modified "2023-10-11" @default.
• W2022101675 title "Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B" @default.
• W2022101675 cites W1965473659 @default.
• W2022101675 cites W2008517556 @default.
• W2022101675 cites W2101032357 @default.
• W2022101675 cites W2102416504 @default.
• W2022101675 doi "https://doi.org/10.7326/0003-4819-143-5-200509060-00018" @default.
• W2022101675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16144900" @default.
• W2022101675 hasPublicationYear "2005" @default.
• W2022101675 type Work @default.
• W2022101675 sameAs 2022101675 @default.
• W2022101675 citedByCount "2" @default.
• W2022101675 crossrefType "journal-article" @default.
• W2022101675 hasAuthorship W2022101675A5024994766 @default.
• W2022101675 hasAuthorship W2022101675A5043626370 @default.
• W2022101675 hasConcept C126322002 @default.
• W2022101675 hasConcept C159047783 @default.
• W2022101675 hasConcept C203014093 @default.
• W2022101675 hasConcept C2522874641 @default.
• W2022101675 hasConcept C2775940106 @default.
• W2022101675 hasConcept C2776178377 @default.
• W2022101675 hasConcept C2776461080 @default.
• W2022101675 hasConcept C2777382497 @default.
• W2022101675 hasConcept C2777410769 @default.
• W2022101675 hasConcept C2777451964 @default.
• W2022101675 hasConcept C2777869810 @default.
• W2022101675 hasConcept C2780040827 @default.
• W2022101675 hasConcept C2780593183 @default.
• W2022101675 hasConcept C2909179924 @default.
• W2022101675 hasConcept C3020491458 @default.
• W2022101675 hasConcept C71924100 @default.
• W2022101675 hasConcept C90924648 @default.
• W2022101675 hasConceptScore W2022101675C126322002 @default.
• W2022101675 hasConceptScore W2022101675C159047783 @default.
• W2022101675 hasConceptScore W2022101675C203014093 @default.
• W2022101675 hasConceptScore W2022101675C2522874641 @default.
• W2022101675 hasConceptScore W2022101675C2775940106 @default.
• W2022101675 hasConceptScore W2022101675C2776178377 @default.
• W2022101675 hasConceptScore W2022101675C2776461080 @default.
• W2022101675 hasConceptScore W2022101675C2777382497 @default.
• W2022101675 hasConceptScore W2022101675C2777410769 @default.
• W2022101675 hasConceptScore W2022101675C2777451964 @default.
• W2022101675 hasConceptScore W2022101675C2777869810 @default.
• W2022101675 hasConceptScore W2022101675C2780040827 @default.
• W2022101675 hasConceptScore W2022101675C2780593183 @default.
• W2022101675 hasConceptScore W2022101675C2909179924 @default.
• W2022101675 hasConceptScore W2022101675C3020491458 @default.
• W2022101675 hasConceptScore W2022101675C71924100 @default.
• W2022101675 hasConceptScore W2022101675C90924648 @default.
• W2022101675 hasIssue "5" @default.
• W2022101675 hasLocation W20221016751 @default.
• W2022101675 hasLocation W20221016752 @default.
• W2022101675 hasOpenAccess W2022101675 @default.
• W2022101675 hasPrimaryLocation W20221016751 @default.
• W2022101675 hasRelatedWork W1995937523 @default.
• W2022101675 hasRelatedWork W1998109795 @default.
• W2022101675 hasRelatedWork W2074136177 @default.
• W2022101675 hasRelatedWork W2333359672 @default.
• W2022101675 hasRelatedWork W2362720187 @default.
• W2022101675 hasRelatedWork W2369779138 @default.
• W2022101675 hasRelatedWork W2405721999 @default.
• W2022101675 hasRelatedWork W2412913209 @default.
• W2022101675 hasRelatedWork W2417568099 @default.
• W2022101675 hasRelatedWork W2466036982 @default.
• W2022101675 hasVolume "143" @default.
• W2022101675 isParatext "false" @default.
• W2022101675 isRetracted "false" @default.
• W2022101675 magId "2022101675" @default.
• W2022101675 workType "article" @default.